Publications, Pharmaceutical

Investigating Breathable HPV-L2 Dry Powder Vaccine using GLA as Amphiphilic Lubricant and Immune-adjuvant

Dry powder respirable vaccines combine the advantage of high patient acceptability with a lack of any requirement for cold chain storage, an important logistical and economic benefit.

This paper describes a proof-of-concept validation of a dry powder human papillomavirus (HPV) respirable vaccine developed using a particle engineering approach. A key characteristic of the developed formulation is the application of glucopyranosyl lipid A (GLA) to the surface of vaccine particles to simultaneously improve aerosolization performance and recognition by the lung immune cells. Extensive in vitro characterization of the resulting formulation was carried out along with in vivo tests to determine lung deposition behavior, following intratracheal administration to mice. A subsequent short-term immunization study provided evidence of an immune response comparable to that achieved via subcutaneous delivery.

Download Publication
10 Dec 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top